the tweed vault  Mar 23



Cannabinoids in clinical practice

The Marihuana for Medical Purposes Regulations have changed the way cannabis is used in clinical practice in Canada. The new regulations have been in place for a year with a resulting dynamic change in the marketplace.

At the end of March the Tweed Medical Outreach team attended the Canadian Consortium for the Investigation of Cannabinoids to enhance their understanding of the recent research into the use of medical marijuana.

The symposia was designed to present updates from key researchers and stakeholders to assist Canadian physicians and nurse practitioners with the safe and effective use of cannabinoids in their practice. The conference presented the science of the endocannabinoid system, the risks, the research efficacy, as well as how to approach cannabinoids as an option in patient care.

The participants were able to discuss cannabinoids in a variety of therapeutic areas including cannabinoids in mental health, managing joint inflammation and pain, evidence of cannabinoids in cancer use, the effects of cannabis on youth, the recently released clinical guidance document for family physicians, and other topics.

The Tweed Medical Outreach team endeavours to provide the healthcare community the most current and relevant medical marijuana information to allow physicians to make the best clinical decisions for their patients.

The team were very engaged with conference attendees at the Tweed booth, providing the most recent information, demonstrating the Volcano vaporizing system, and answering some of the most frequent questions doctors have.

The two most frequent questions were “How are my patients registered with your business?” and “How does a patient initiate therapy once they are a registered?”

Patients are registered by filling out a medical document and a registration document and Tweed takes care of the rest. More information on registration is available in this video.

We recommend that patients initiate cannabis therapy by starting with strains that are lower in THC. Argyle, for example has approximately 5% THC and 6% CBD. “Low and Slow” is a good rule of thumb for patients who are new to cannabis to ensure that the early experiences are positive before transitioning to something with more potency.

In total the conference included 17 seminar presentations by Canadian physicians and researchers who highlighted the need for additional investigation into the use of cannabinoids in pain management, cannabinoids in driving, and illustrates the need for ongoing research into the many facets of cannabinoids and their impact on the receptors of pain, the brain and oncology.

Look for a Medical Outreach member to attend your office shortly. The field provides ongoing research regularly there is always something new to discuss.

Suzanne Sarrazin
Medical Outreach.

other stories you may be interested in

  • Here’s to Future Growth in the New Year

    As we prepare for what promises to be a banner year for Canada’s budding cannabis industry, we’re taking a little time to reflect on some of the milestones we reached in 2016...

  • New DNA Certified Strains Coming To Tweed Shop

    “Let me ask you guys: How do you fill those pots?” The temperature is tropical inside a glowing flowering room at Tweed headquarters on the fourth trip to Smiths Falls for DNA Genetics...

  • Patients Not Forgotten By Legalization Task Force

    Last week, the task force assembled by Justin Trudeau’s Liberal government to assess the prospect of cannabis legalization released its recommendations...